Utama › Nefritis Lupus › Pennsylvania
Kajian klinikal Nefritis Lupus di Pennsylvania
7 kajian untuk Nefritis Lupus sedang mencari peserta di lokasi di Pennsylvania.
Bandar di Pennsylvania
Teks kajian rasmi (Bahasa Inggeris)
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
- Temple University, Philadelphia
Mengambil pesertaFasa 2
Umur 18 hingga 100 · Semua jantina · Dikemas kini 1 Okt 2026 · NCT05268289CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
- Children's Hospital of Philadelphia, Philadelphia
Mengambil pesertaFasa 1/2
Umur 10 hingga 29 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT06839976A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
- Fox Chase Cancer Center- Temple BMT, Philadelphia
Mengambil pesertaFasa 2
Umur 16 hingga 70 · Semua jantina · Dikemas kini 17 Sep 2026 · NCT07328581VIBRANT: VIB4920 for Active Lupus Nephritis
- Penn State Health Milton S. Hershey Medical Center: Division of Rheumatology, Hershey
- Temple University, Lewis Katz School of Medicine, Department of Medicine: Nephrology, Philadelphia
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT05201469RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
- Children's Hospital of Philadelphia, Philadelphia
Mengambil pesertaFasa 1/2
Umur 18 hingga 65 · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT06121297PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
- Rheumatic Disease Associates, Ltd., Willow Grove
Mengambil pesertaFasa 4
Umur 18 hingga 75 · Semua jantina · Dikemas kini 3 Ogo 2026 · NCT07611214A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Jefferson Einstein Hospital Philadelphia, Philadelphia
Mengambil pesertaFasa 1
Umur 12 hingga 70 · Semua jantina · Dikemas kini 22 Mei 2026 · NCT06308978Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.